Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 1

Status

Recruiting 3Completed 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Lymphoid 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 51Lung Neoplasms 24Parkinson Disease 4, Autosomal Dominant Lewy Body 22Squamous Cell Carcinoma of Head and Neck 18Neoplasm Metastasis 17Melanoma 17Neoplasms 16Endometrial Neoplasms 14Colorectal Neoplasms 14Breast Neoplasms 14Triple Negative Breast Neoplasms 12Ovarian Neoplasms 11Head and Neck Neoplasms 9Pancreatic Neoplasms 7Urinary Bladder Neoplasms 6Carcinoma, Transitional Cell 6Recurrence 5Lymphoma 5Hodgkin Disease 5Carcinoma, Renal Cell 5Esophageal Neoplasms 4Carcinoma 4Brain Neoplasms 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Fallopian Tube Neoplasms 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Ureteral Neoplasms 2

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 7Cisplatin 5pembrolizumab 4durvalumab 4Carboplatin 4cemiplimab 3Radiation 3Platinum 3Paclitaxel 3Cetuximab 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3(225)Ac-DOTA-c(RGDyK) 3cabozantinib 2atezolizumab 2Radiotherapy 2Pemetrexed 2Nivolumab 2Immunoglobulin G 2Docetaxel 2Disulfides 2ALT-803 2130-nm albumin-bound paclitaxel 2zipalertinib 1repotrectinib 1poly ICLC 1ipatasertib 1fludarabine phosphate 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma × pembrolizumab × 30 days × Clear all
NCT07222566 2026-06-04

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Pfizer

Phase 3 Recruiting
1,410 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT06589804 2026-06-03

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

National Cancer Institute (NCI)

Phase 3 Recruiting
158 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT03789097 2026-05-22

Vaccination With Flt3L, Radiation, and Poly-ICLC

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
17 enrolled
BreastHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

NCT06312137 2026-05-22

TroFuse-019

Merck Sharp & Dohme LLC

Phase 3 Recruiting
780 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡